HC Wainwright Issues Optimistic Outlook for ATOS Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Stock analysts at HC Wainwright upped their Q3 2025 EPS estimates for Atossa Therapeutics in a research report issued to clients and investors on Tuesday, May 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.06) per share for the quarter, up from their previous forecast of ($0.07). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2025 earnings at ($0.24) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at ($0.21) EPS and FY2029 earnings at ($0.16) EPS.

Atossa Therapeutics (NASDAQ:ATOS) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Separately, Ascendiant Capital Markets increased their price target on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the stock a “buy” rating in a report on Monday, April 21st.

Atossa Therapeutics Stock Down 1.6%

NASDAQ ATOS opened at $0.97 on Friday. The stock has a market capitalization of $125.31 million, a P/E ratio of -4.41 and a beta of 1.01. Atossa Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.71. The firm has a 50-day moving average price of $0.73 and a 200 day moving average price of $0.92.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. Renaissance Technologies LLC grew its position in Atossa Therapeutics by 18.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company’s stock worth $1,471,000 after buying an additional 247,562 shares during the period. JPMorgan Chase & Co. grew its position in Atossa Therapeutics by 141.4% during the fourth quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company’s stock worth $341,000 after buying an additional 211,654 shares during the period. Nuveen LLC acquired a new position in Atossa Therapeutics during the first quarter worth about $115,000. Virtu Financial LLC grew its position in Atossa Therapeutics by 311.1% during the fourth quarter. Virtu Financial LLC now owns 208,196 shares of the company’s stock worth $197,000 after buying an additional 157,549 shares during the period. Finally, Barclays PLC grew its position in shares of Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after purchasing an additional 123,683 shares during the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.